A multi-modal study on cerebrovascular dysfunction in cognitive decline of de novo Parkinson's disease
Hongwei Li1, Xiali Shao2, Jia Jia3
1Institute of Science and Technology for Brain-inspired Intelligence, Fudan University, Shanghai, China.
Background:
Vascular risk factors are increasingly implicated in Parkinson's disease (PD), but the role of altered cerebrovascular dysfunction in early-stage PD remains unclear. Here, we investigated resting-state cerebrovascular reactivity (RS-CVR), cerebral blood flow (CBF), arterial morphological changes, and corresponding alterations in functional connectivity density (FCD) in de novo PD patients with different cognitive status.
Methods:
25 de novo PD patients with mild cognitive impairment (PD-MCI), 34 with normal cognition (PD-NC), and 48 healthy controls (HCs) underwent neuropsychological assessments and multimodal MRI. CBF derived from arterial spin labeling, RS-CVR and FCD generated from resting-state functional MRI and the arterial morphology extracted from the magnitude images of multi-echo gradient echo.
Results:
RS-CVR significantly decreased in PD patients, particularly in the left occipital gyrus and posterior cerebral artery (PCA) territories. Long-range FCD was reduced in the left inferior occipital gyrus in both PD-NC and PD-MCI compared to HCs (p = 0.005, p < 0.001). In PD-MCI, negative correlations between Stroop Color-Word Test time and RS-CVR in the distal right PCA (r = -0.71, pFDR = 0.030) and middle left PCA (r = -0.66, pFDR = 0.044) were observed. A significant correlation was found between decreased long-range FCD in the left inferior occipital gyrus and poorer Trail Making Test Part B performance (r = -0.63, pFDR = 0.029) in the PD-MCI. No significant differences in CBF, but significant dilation of the left PCA and compensatory CBF increases in the corresponding territory in PD-MCI were found (r = 0.57, pFDR = 0.023).
Discussion:
Microvascular dysfunction, rather than perfusion defects, might underlie early-stage of the de novo PD, especially in the patients with PD-MCI.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Neural Regulation


